Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Merck and Indian CDMO Aragen have signed a memorandum of understanding for the manufacturing and development of monoclonal antibodies, Merck said Friday.
CDMO Scorpius is delaying its public offering that was previously announced in March, the company said Friday. Scorpius still intends to sell 12,500,000 shares at $1 apiece.
NorthStar Medical Radioisotopes and Convergent Therapeutics are partnering to develop the radiopharma biotech’s lead asset, dubbed CONV01-α, which is being investigated for prostate cancer. NorthStar will manufacture CONV01-α, supply the isotope Ac-225 and help with R&D activities, according to a Tuesday release.
Radiopharma company Blue Earth Therapeutics is expanding its manufacturing agreement with Austrian manufacturer Seibersdorf Laboratories, according to a Tuesday release. Seibersdorf will now also manufacture Blue Earth’s actinium-225-based radioligand therapy.
Cell and gene therapy CDMO ViroCell Biologics has finished an oversubscribed investment round but did not disclose financial details. The raise will be used to help the company grow with increased demand for its viral vector manufacturing services, the company said Wednesday.
Iceland-based biotech PLAIO has raised €4.3 million ($4.7 million) for its AI product designed to improve pharma supply chains, the company said Wednesday.
Baxter is “urgently” recalling a batch of its heparin injection due to high levels of endotoxins, which can cause issues like toxic shock, organ failure and even death. The batch being recalled was distributed in the US to wholesalers and healthcare facilities between March 2023 and August 2023.